Calhoun Lesley Ann 4

What Happened
Lesley Ann Calhoun, who serves as Chief Operating Officer and Chief Financial Officer of Aligos Therapeutics (ALGS), received a grant of 37,485 derivative shares on March 9, 2026. The Form 4 reports the shares were acquired at $0.00 (transaction code A — award/grant); the filing lists $0 total cash value. This is a compensation grant (an option-style award with vesting), not a sale or open-market purchase.

Key Details

• Transaction date: 2026-03-09; Form 4 filed 2026-03-11 (appears timely).
• Amount: 37,485 derivative shares granted; reported acquisition price $0.00.
• Vesting: 1/48th of the total vests in equal monthly installments starting March 9, 2026; 100% vests on the fourth anniversary (March 9, 2030), subject to continued service. (See footnote F1.)
• Shares owned after transaction: not reported in this filing.
• Transaction code: A = Award/Grant (derivative). No indication of immediate sale or cashless exercise in this filing.

Context
This was a compensation-related option/award grant that vests over four years; such grants are routine for executives and don’t by themselves signal buying or selling decisions. Because these are derivative awards, the holder must wait for vesting to exercise any underlying rights; terms like exercise price or post-vesting treatment may be in separate agreements. The filing appears timely (filed two days after the grant date).